TY - JOUR
T1 - Osteogenesis imperfecta at the beginning of bone and joint decade
AU - Primorac, D.
AU - Rowe, D. W.
AU - Mottes, M.
AU - Barišić, I.
AU - Antičević, D.
AU - Mirandola, S.
AU - Gomez Lira, M.
AU - Kalajzić, I.
AU - Kušec, V.
AU - Glorieux, F. H.
PY - 2001
Y1 - 2001
N2 - Osteogenesis imperfecta (OI), or brittle bone disease, is a heritable disorder characterized by increased bone fragility. Four different types of the disease are commonly distinguished, ranging from a mild condition (type I) to a lethal one (type II). Types III and IV are the severe forms surviving the neonatal period. In most cases, there is a reduction in the production of normal type I collagen or the synthesis of abnormal collagen as a result of mutations in the type I collagen genes. These "classic" forms of OI are described in this review. There are instances, however, where alterations in bone matrix components, other than type I collagen, are the basic abnormalities of the OI. Recently, three such discrete types have been identified by histomorphometric evaluation (types V and VI) and linkage analysis (Rhizomelic OI). They provide evidence for the as yet poorly understood complexity of the phenotype-genotype correlation in OI. We also discus bisphosphonates treatment as well as fracture management and surgical correction of deformities observed in the patients with OI. However, ultimately, strengthening bone in OI will involve steps to correct the underlying genetic mutations that are responsible for this disorder. Thus, we also describe different genetic therapeutic approaches that have been tested either on OI cells or on available OI murine models.
AB - Osteogenesis imperfecta (OI), or brittle bone disease, is a heritable disorder characterized by increased bone fragility. Four different types of the disease are commonly distinguished, ranging from a mild condition (type I) to a lethal one (type II). Types III and IV are the severe forms surviving the neonatal period. In most cases, there is a reduction in the production of normal type I collagen or the synthesis of abnormal collagen as a result of mutations in the type I collagen genes. These "classic" forms of OI are described in this review. There are instances, however, where alterations in bone matrix components, other than type I collagen, are the basic abnormalities of the OI. Recently, three such discrete types have been identified by histomorphometric evaluation (types V and VI) and linkage analysis (Rhizomelic OI). They provide evidence for the as yet poorly understood complexity of the phenotype-genotype correlation in OI. We also discus bisphosphonates treatment as well as fracture management and surgical correction of deformities observed in the patients with OI. However, ultimately, strengthening bone in OI will involve steps to correct the underlying genetic mutations that are responsible for this disorder. Thus, we also describe different genetic therapeutic approaches that have been tested either on OI cells or on available OI murine models.
UR - http://www.scopus.com/inward/record.url?scp=0034865790&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034865790&partnerID=8YFLogxK
M3 - Review article
C2 - 11471191
AN - SCOPUS:0034865790
SN - 0353-9504
VL - 42
SP - 393
EP - 415
JO - Croatian Medical Journal
JF - Croatian Medical Journal
IS - 4
ER -